SR One Capital Management
$1.0B 13F equity value
17 Holdings
Quarter ended June 30, 2026
The latest 13F on file for SR One Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MANE | Veradermics, Inc. | 2,401,868 | $295M | 28.4% |
| ZBIO | Zenas BioPharma, Inc | 5,037,854 | $128M | 12.3% |
| CRSP | CRISPR Therapeutics AG | 2,038,763 | $111M | 10.7% |
| AVLN | Avalyn Pharma, Inc | 3,308,649 | $109M | 10.5% |
| DSGN | Design Therapeutics, Inc. | 6,526,476 | $94M | 9.1% |
| ODTX | Odyssey Therapeutics, Inc. | 3,794,883 | $71M | 6.8% |
| ALMS | Alumis Inc. | 1,959,896 | $55M | 5.3% |
| ORIC | ORIC Pharmaceuticals, Inc. | 4,615,384 | $50M | 4.8% |
| MLYS | Mineralys Therapeutics Inc. | 1,563,966 | $42M | 4.1% |
| SPRY | ARS Pharmaceuticals, Inc. | 4,012,903 | $32M | 3.1% |
Track SR One Capital Management's 13F portfolio: $1.0B in reported holdings, 17 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}